Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 11/06/25
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual MeetingGlobeNewsWire • 11/03/25
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business UpdateGlobeNewsWire • 10/30/25
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 TranscriptSeeking Alpha • 10/04/25
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?Zacks Investment Research • 09/12/25
Allogene Therapeutics Announces Participation in Upcoming Investor ConferenceGlobeNewsWire • 08/27/25
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business UpdateGlobeNewsWire • 08/13/25
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business UpdateGlobeNewsWire • 08/06/25
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell LymphomaGlobeNewsWire • 08/01/25
Why Is Allogene Therapeutics (ALLO) Up 52.2% Since Last Earnings Report?Zacks Investment Research • 06/12/25
All You Need to Know About Allogene Therapeutics (ALLO) Rating Upgrade to BuyZacks Investment Research • 06/04/25
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCOGlobeNewsWire • 06/01/25
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)Seeking Alpha • 05/28/25
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-CelGlobeNewsWire • 05/22/25
Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 05/15/25